AdAlta Leads Healthcare Stocks as Biotech Funding and Trial Updates Continue

• AdAlta rose 16.67% after manufacturing partner Oribiotech signed a 10-year deal worth up to US$120 million.
• Vectus fell 10.00% despite a FY2026 profit, as most of the result came from a transaction involving XORTX shares and warrants.
• Cambium Bio secured firm commitments for a proposed A$7.1 million placement to fund its Elate Ocular Phase 3 programme.
• Proteomics International began selling two Promarker tests through Healius, but wider sales are not expected until Q2 FY27.